Lutetium Lu 177-PSMA-617

DRUG2 trials

Sponsors

University of California, San Francisco, Vadim S Koshkin

Conditions

Castration Levels of TestosteroneCastration-Resistant Prostate CarcinomaMetastatic Castration-resistant Prostate CancerMetastatic Castration-resistant Prostate CarcinomaMetastatic Prostate AdenocarcinomaMetastatic Prostate CarcinomaProstate AdenocarcinomaStage IV Prostate Cancer

Phase 1

177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer

CompletedNCT03805594

University of California, San FranciscoCastration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma +4

Start: 2019-05-10End: 2024-01-10Updated: 2025-02-25

Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer

RecruitingNCT05113537

Vadim S KoshkinCastration-Resistant Prostate Carcinoma, Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Carcinoma +4

Start: 2022-07-08End: 2028-12-31Target: 30Updated: 2026-07-24

Related Papers

Abstract 2558: Multi-omic single-cell assessment of castration-resistant prostate cancer patients receiving177Lu-PSMA-617 and pembrolizumab shows timing of radioligand therapy alters immune response

Cancer Research2026-04-03

Single-dose <sup>177</sup>Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial.

2023-11-0152 citations

Immunogenic priming with <sup>177</sup>Lu-PSMA-617 plus pembrolizumab in metastatic castration resistant prostate cancer (mCRPC): A phase 1b study.

Journal of Clinical Oncology2021-05-2031 citations